Centene (CNC) has opened 2026 with Q1 revenue of US$49.9b and basic EPS of US$3.13, setting a clear marker after a volatile run of quarterly earnings. Over recent periods, revenue has moved from US$43.3b in Q1 2025 to US$45.1b in Q4 2025 and now US$49.9b in Q1 2026. Basic EPS has swung from US$2.64 to losses of US$0.51, US$13.50 and US$2.24 per share before returning to a profit of US$3.13 per share in the latest quarter. For investors, that combination of large revenue, sharp EPS swings and a current share price around US$49.57 puts the focus squarely on how durable Centene’s margins look after this print.

See our full analysis for Centene.

With the latest earnings on the table, the next step is to weigh these revenue and EPS patterns against the main Centene narratives to see which stories the numbers support and which they call into question.

Trailing losses still loom over Q1 profit

• Across the last 12 months, Centene generated about US$179.5b of revenue but recorded a net loss of US$6.4b and trailing basic EPS of US$13.10 loss per share, even though Q1 2026 on its own delivered net income of US$1.5b and basic EPS of US$3.13.
• Consensus narrative points to expected margin recovery in Medicaid and Medicare, yet the trailing 12 month loss of US$6.4b sits against analysts expecting earnings around US$2.1b and 7% annual revenue growth, which means:
  • Forecasts for steadier earnings contrast with the recent five year pattern where losses worsened by about 32.2% per year, so the Q1 profit does not yet line up with that longer record.
  • Expected Medicaid and Medicare margin improvement must first overcome the current negative trailing EPS of US$13.10, so readers should see this quarter as one data point alongside a still loss making recent history.

DCF value far above US$49.57 share price

• The shares trade around US$49.57 compared with a reported DCF fair value of about US$213.54 and a single analyst price target figure of US$43.47, while the P/S ratio of 0.1x sits well below the 1.5x peer average and 1.2x US healthcare industry figure.
• Bulls argue that low multiples and the gap to DCF fair value leave room for upside, but the same data also highlight clear hurdles:
  • The stock price is below the cited DCF fair value and above the analyst target figure of US$43.47, so investors weighing the bullish case need to reconcile a strong implied DCF value with a more conservative analyst target.
  • Forecast earnings growth of 69.46% per year and an expectation of profitability within three years sit beside modest 3.4% revenue growth over the last year, so the valuation appeal depends on earnings improving much faster than revenue has recently grown.

On these numbers, bulls are leaning on rapid earnings recovery and a wide DCF gap, while the current price still reflects cautious views around recent losses and slower top line growth, which are explored in more depth in the 🐂 Centene Bull Case

Bears focus on slow 3.4% revenue growth

• Revenue across the last year is described as growing about 3.4% per year, below the 11.1% US market figure cited in the data, while losses over five years worsened at an annual rate of 32.2% even as trailing 12 month revenue reached about US$179.5b.
• Bears highlight regulatory pressure and rising medical costs as threats to margins, and the reported figures leave several points to check against that view:
  • The combination of unprofitable trailing 12 month operations and a multi year 32.2% annual deterioration in losses is consistent with concerns that higher costs and tight reimbursement can weigh heavily on net income.
  • However, the Q1 2026 profit of US$1.5b and EPS of US$3.13 show that individual periods can still be profitable, so readers following the bearish view may want to track whether future quarters look more like this one or like the recent loss making stretch.

Skeptics point to the weak trailing 12 month record and slower 3.4% revenue growth as reasons to question how quickly margins can improve, and that cautious angle is unpacked further in the 🐻 Centene Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Centene on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of profits, losses and valuation gaps still feels mixed, treat that as a prompt to look closer and decide for yourself. To see what optimism in the data looks like in practice, start with the 3 key rewards.

See What Else Is Out There

Centene’s mix of trailing 12 month losses, slow 3.4% revenue growth and sharp EPS swings suggests earnings quality and consistency are still key pressure points.

If that uncertainty around profits makes you uneasy, it could be worth checking companies with steadier metrics and stronger fundamentals via the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.